Pentwater exits Centessa Pharmaceuticals (CNTA) with reported 0% ownership

Rhea-AI Filing Summary

Pentwater Capital Management LP and Matthew Halbower report that they no longer beneficially own any ordinary shares of Centessa Pharmaceuticals plc, represented by ADSs with CUSIP 152309100. Their reported beneficial ownership is 0 shares and 0% of the class, with no sole or shared voting or dispositive power. The filing confirms they now fall under the category of ownership of 5 percent or less of this class of Centessa securities.

Key Figures

Beneficial ownership: 0.00 shares Percent of class: 0% Nominal share value: GBP 0.002 per share +1 more

4 metrics

Beneficial ownership 0.00 shares Ordinary shares of Centessa Pharmaceuticals plc reported by each reporting person

Percent of class 0% Percent of Centessa ordinary shares beneficially owned by the reporting persons

Nominal share value GBP 0.002 per share Nominal value of Centessa Pharmaceuticals plc ordinary shares

CUSIP for ADSs 152309100 CUSIP assigned to American Depositary Shares representing Centessa ordinary shares

Key Terms

beneficially owned, American Depositary Shares, investment adviser, Ownership of 5 percent or less of a class, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: The information required by Item 4(a) is set forth"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

American Depositary Shares financial

"assigned to the American Depositary Shares ("ADSs") of the Company"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

investment adviser financial

"the investment adviser to certain funds (the "Pentwater Funds")"

An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

Ownership of 5 percent or less of a class financial

"Item 5. | Ownership of 5 Percent or Less of a Class."

dispositive power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

What does the Schedule 13G/A filing disclose about CNTA ownership by Pentwater Capital Management?

The filing states that Pentwater Capital Management LP now beneficially owns 0 ordinary shares of Centessa Pharmaceuticals plc, corresponding to 0% of the class, with no sole or shared voting or dispositive power reported.

What is Matthew Halbower’s reported ownership in Centessa Pharmaceuticals (CNTA)?

Matthew Halbower reports beneficial ownership of 0 ordinary shares of Centessa Pharmaceuticals plc, representing 0% of the class. He also has no sole or shared voting or dispositive power over Centessa shares in this disclosure.

Why is Pentwater listed as owning 5 percent or less of CNTA stock?

Item 5 notes that the reporting persons fall under “Ownership of 5 percent or less of a class”. Their current beneficial ownership is reported as 0 shares and 0% of Centessa’s ordinary shares represented by ADSs.

Which securities of Centessa Pharmaceuticals (CNTA) are covered in this Schedule 13G/A?

The filing covers ordinary shares of Centessa Pharmaceuticals plc with nominal value GBP 0.002 per share, represented by American Depositary Shares (ADSs) that have CUSIP 152309100 and were quoted on the Nasdaq Global Select Market.

Who are the reporting persons in this CNTA Schedule 13G/A amendment?

The reporting persons are Pentwater Capital Management LP, a Delaware limited partnership and investment adviser to certain funds, and Matthew Halbower, a U.S. citizen and sole shareholder of MCH PWCM Holdings Inc., the general partner of the Investment Manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:28 PM Accepted by SEC EDGAR 08/14/2026 - 04:21 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Centessa Pharmaceuticals plc

(Name of Issuer)

Ordinary Shares, nominal value GBP 0.002 per share

(Title of Class of Securities)

152309100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 152309100

1

Names of Reporting Persons

Pentwater Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 152309100

1

Names of Reporting Persons

Matthew Halbower

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Centessa Pharmaceuticals plc
(b)	Address of issuer's principal executive offices: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT, United Kingdom
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Pentwater Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to certain funds (the "Pentwater Funds"), with respect to the ordinary shares, nominal value GBP 0.002 per share ("Ordinary Shares"), of Centessa Pharmaceuticals plc, a public limited liability company incorporated under the laws of England and Wales (the "Company"), represented by ADSs (as defined below) that were directly held by the Pentwater Funds; and (ii) Mr. Matthew Halbower ("Mr. Halbower"), the sole shareholder of MCH PWCM Holdings Inc., the general partner of the Investment Manager, with respect to the Ordinary Shares, represented by ADSs, that were directly held by the Pentwater Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." There is no CUSIP assigned to the Ordinary Shares. The CUSIP number 152309100 has been assigned to the American Depositary Shares ("ADSs") of the Company, which were quoted on the Nasdaq Global Select Market under the symbol "CNTA."
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 1001 10th Avenue South, Suite 216, Naples, FL 34102.
(c)	Citizenship: The Investment Manager is a Delaware limited partnership. Mr. Halbower is a citizen of the United States.
(d)	Title of class of securities: Ordinary Shares, nominal value GBP 0.002 per share
(e)	CUSIP No.: 152309100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(b)	Percent of class: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pentwater Capital Management LP

Signature:	/s/ Matthew Halbower
Name/Title:	By: MCH PWCM Holdings Inc., General Partner, By: Matthew Halbower, Chief Executive Officer
Date:	08/14/2026

Matthew Halbower

Signature:	/s/ Matthew Halbower
Name/Title:	Matthew Halbower, individually
Date:	08/14/2026